Barinthus Biotherapeutics Reports $66.5 Million Net Loss and Strategic Shift Towards Immunology

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, reported a net loss of $66.5 million for the year ended December 31, 2025, compared to a net loss of $61.2 million for the previous year. The company's revenue decreased to $0 from $15.0 million in 2024, primarily due to the strategic decision by AstraZeneca to initiate the withdrawal of marketing authorization for Vaxzevria in Europe, which impacted royalty payments to Barinthus Bio. Research and development expenses decreased from $42.2 million in 2024 to $25.6 million in 2025, reflecting a strategic business refocus and restructuring to prioritize immunology and inflammation indications. General and administrative expenses increased from $29.7 million in 2024 to $40.8 million in 2025, mainly due to a $12.0 million change in foreign exchange gains and losses and an increase of $6.5 million in professional fees.

The company's strategic shift towards immunology and inflammation (I&I) indications led to the deprioritization of its infectious disease and oncology programs, resulting in a 65% workforce reduction and the expected closure of its U.K. site. Key operational developments included the advancement of VTP-1000, an antigen-specific immune tolerance candidate for celiac disease, with the Phase 1 AVALON clinical trial showing promising tolerability and dose-dependent effects. The company is actively seeking a partner for VTP-300, a hepatitis B immunotherapy, after presenting Phase 2 clinical trial data demonstrating meaningful reductions in hepatitis B surface antigen (HBsAg).

In September 2025, Barinthus Bio entered into a Merger Agreement with Clywedog Therapeutics, Inc., an all-stock transaction expected to close in the second quarter of 2026. The combined entity, to be named Clywedog Therapeutics Holdings, Inc., will focus on metabolic and autoimmune diseases, with four clinical data milestones anticipated within 18 months of the transaction's completion. As of December 31, 2025, Barinthus Bio had 14 full-time and part-time employees, with 57% of the workforce and 43% of leadership positions held by women.

Looking ahead, Barinthus Biotherapeutics anticipates that its existing cash, cash equivalents, restricted cash and other financial resources will enable it to fund its operating expenses and capital expenditure requirements for at least the next 12 months. The company's future capital requirements will depend on various factors, including the progress and costs of its research and development programs, the timing of regulatory approvals, and its ability to establish collaborations and strategic licensing arrangements. The company's management believes that it has sufficient cash and other financial resources to support its operations for at least the next 12 months, without additional financing.